RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone310-478-7808
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$975.15 million
Profitability
Miscellaneous
Employees7,869
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
RadNet (NASDAQ:RDNT) Frequently Asked Questions
What is RadNet's stock symbol?
RadNet trades on the NASDAQ under the ticker symbol "RDNT."
How were RadNet's earnings last quarter?
RadNet Inc. (NASDAQ:RDNT) posted its quarterly earnings data on Thursday, August, 8th. The medical research company reported $0.10 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.02. The medical research company earned $289.10 million during the quarter, compared to analyst estimates of $272.36 million. RadNet had a return on equity of 18.91% and a net margin of 3.33%. The firm's revenue for the quarter was up 18.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.11 EPS. View RadNet's Earnings History.
When is RadNet's next earnings date?
What guidance has RadNet issued on next quarter's earnings?
RadNet issued an update on its FY 2019 earnings guidance on Thursday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.1-1.15 billion, compared to the consensus revenue estimate of $1.09 billion.
What price target have analysts set for RDNT?
1 analysts have issued twelve-month target prices for RadNet's shares. Their forecasts range from $17.50 to $17.50. On average, they anticipate RadNet's share price to reach $17.50 in the next year. This suggests a possible upside of 18.9% from the stock's current price. View Analyst Price Targets for RadNet.
What is the consensus analysts' recommendation for RadNet?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for RadNet.
Has RadNet been receiving favorable news coverage?
Media coverage about RDNT stock has been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RadNet earned a news impact score of -3.2 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for RadNet.
Are investors shorting RadNet?
RadNet saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 902,200 shares, an increase of 14.7% from the August 15th total of 786,500 shares. Based on an average daily volume of 228,900 shares, the short-interest ratio is currently 3.9 days. Currently, 2.2% of the shares of the stock are short sold. View RadNet's Current Options Chain.
Who are some of RadNet's key competitors?
Some companies that are related to RadNet include Natera (NTRA), Genomic Health (GHDX), InVitae (NVTA), Veracyte (VCYT), CareDx (CDNA), Personalis (PSNL), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC) and Avant Diagnostics (AVDX).
What other stocks do shareholders of RadNet own?
Who are RadNet's key executives?
RadNet's management team includes the folowing people:
- Dr. Howard G. Berger, Chairman, Pres, CEO & Treasurer (Age 73)
- Mr. Mark D. Stolper, Exec. VP & CFO (Age 48)
- Mr. Norman R. Hames, Pres, COO of Western Operations & Director (Age 63)
- Mr. Stephen M. Forthuber, Pres & COO of Eastern Operations (Age 58)
- Mr. Ranjan Jayanathan, Chief Information Officer & GM of Radiology Information Technology Division
Who are RadNet's major shareholders?
RadNet's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dalton Greiner Hartman Maher & Co. (2.48%) and Assenagon Asset Management S.A. (0.20%). Company insiders that own RadNet stock include David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Marvin S Cadwell, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View Institutional Ownership Trends for RadNet.
Which major investors are buying RadNet stock?
RDNT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Dalton Greiner Hartman Maher & Co.. View Insider Buying and Selling for RadNet.
How do I buy shares of RadNet?
Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is RadNet's stock price today?
One share of RDNT stock can currently be purchased for approximately $14.72.
How big of a company is RadNet?
RadNet has a market capitalization of $737.91 million and generates $975.15 million in revenue each year. The medical research company earns $32.24 million in net income (profit) each year or $0.66 on an earnings per share basis. RadNet employs 7,869 workers across the globe.View Additional Information About RadNet.
What is RadNet's official website?
How can I contact RadNet?
RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]
MarketBeat Community Rating for RadNet (NASDAQ RDNT)
MarketBeat's community ratings are surveys of what our community members think about RadNet and other stocks. Vote "Outperform" if you believe RDNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
